Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination

Pascual‐Pasto, Guillem; Olaciregui, Nagore G.; Vilà-Ubach, Mònica; Paco, Sonia; Monterrubio, Carles; Rodríguez, Elisa Boucourt; Winter, Ursula; Batalla-Vilacis, Mireia; Català, Jaume; Salvador, Héctor; Parareda, Andreu; Schaiquevich, Paula; Suñol, Mariona; Lavarino, Cinzia; Torres, Carmen de; Chantada, Guillermo

doi:10.1016/j.canlet.2016.06.012

Cited by 24 publications

(35 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum-free, growth factor-supplemented culture medium is used to expand the small tumor fragments obtained from the enucleated eyes and maintain retinoblastoma cells in culture. This method selects stem-like cells that grow as floating tumor spheres resembling tumor seeding, as opposed to culture medium with bovine serum that promotes cell differentiation (Bond et al, 2013;Ma et al, 2011;Pascual-Pasto et al, 2016).…”

Section: Animal Modelsmentioning

confidence: 99%

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Munier

Beck‐Popovic

Chantada

et al. 2019

Progress in Retinal and Eye Research

Self Cite

160

157

View full text Add to dashboard Cite

Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a "state of metastatic grace" never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the "state of metastatic grace", with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.

show abstract

Section: Animal Modelsmentioning

confidence: 99%

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Munier

Beck‐Popovic

Chantada

et al. 2019

Progress in Retinal and Eye Research

Self Cite

160

157

View full text Add to dashboard Cite

show abstract

“…Selected tumor models were characterized for GD2 antigen expression in cultured cells by an immunofluorescence method already described [36]. All models were analyzed for relative mRNA expression of GD2 synthase [beta-1,4-N-acetyl-galactosaminyl transferase (GalNAc-T)] by real-time quantitative PCR (RT-qPCR), as previously described [36].…”

Section: Methodsmentioning

confidence: 99%

“…All models were analyzed for relative mRNA expression of GD2 synthase [beta-1,4-N-acetyl-galactosaminyl transferase (GalNAc-T)] by real-time quantitative PCR (RT-qPCR), as previously described [36]. The expression of the GD2 antigen in selected PDX models was further studied by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded tissue sections as previously described [37].…”

Section: Methodsmentioning

confidence: 99%

Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8

Monterrubio

Paco

Olaciregui

et al. 2017

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

Neuroblastoma is a pediatric solid tumor with high expression of the tumor associated antigen disialoganglioside GD2. Despite initial response to induction therapy, nearly 50% of high-risk neuroblastomas recur because of chemoresistance. Here we encapsulated the topoisomerase-I inhibitor SN-38 in polymeric nanoparticles (NPs) surface-decorated with the anti-GD2 mouse mAb 3F8 at a mean density of seven antibody molecules per NP. The accumulation of drug-loaded NPs targeted with 3F8 versus with control antibody was monitored by microdialysis in patient-derived GD2-expressing neuroblastoma xenografts. We showed that the extent of tumor penetration by SN-38 was significantly higher in mice receiving the targeted nano-drug delivery system when compared to non-targeted system or free drug. This selective penetration of the tumor extracellular fluid translated into a strong anti-tumor effect prolonging survival of mice bearing GD2-high neuroblastomas in vivo.

show abstract

“…As shown, the method resulted linear in the evaluated range with marked sensitivity. Moreover, although it would be extremely useful to assess the developed technique in an in vivo animal model, the currently available tumour-bearing animal models are xenograft mice that do not allow for replicating the intravitreal technique as performed in humans due to anatomical restrictions 10. Noteworthy, cell recovery from filter paper was almost 100% at different cell loads with no interference from paper components.…”

Section: Discussionmentioning

confidence: 99%

Assessment of retinoblastoma RNA reflux after intravitreal injection of melphalan

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination

Cited by 24 publications

References 35 publications

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8

Assessment of retinoblastoma RNA reflux after intravitreal injection of melphalan

Contact Info

Product

Resources

About